57892-71-4

Basic information

• Product Name: 2-(CHLOROMETHYL)IMIDAZO[1,2-A]PYRIMIDINE
• Synonyms: 2-(CHLOROMETHYL)IMIDAZO[1,2-A]PYRIMIDINE;imidazo[1,2-a]pyrimidine, 2-(chloromethyl)-;2-(chloromethyl)imidazo[1,2-a]pyrimidine(SALTDATA: FREE)
• CAS NO: 57892-71-4
• Molecular Formula: C₇H₆ClN₃
• Molecular Weight: 167.6
• Mol File: 57892-71-4.mol

Chemical Properties

• Appearance: /
• Density: 1.42g/cm³
• Refractive Index: 1.678
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(CHLOROMETHYL)IMIDAZO[1,2-A]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(CHLOROMETHYL)IMIDAZO[1,2-A]PYRIMIDINE(57892-71-4)
• EPA Substance Registry System: 2-(CHLOROMETHYL)IMIDAZO[1,2-A]PYRIMIDINE(57892-71-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 57892-71-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-(Chloromethyl)imidazo[1,2-a]pyrimidine is utilized as a key intermediate in the synthesis of biologically active compounds, playing a crucial role in the creation of novel therapeutic agents. Its presence in the molecular structure of these agents can potentially enhance their pharmacological properties, leading to the development of more effective treatments for a variety of diseases and conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(Chloromethyl)imidazo[1,2-A]pyrimidine is employed as a structural component in the design and synthesis of new drugs. Its unique reactivity and the ability to form various chemical bonds make it a valuable tool for creating molecules with specific therapeutic targets, thereby contributing to the advancement of personalized medicine and precision healthcare.
Used in Organic Synthesis:
2-(Chloromethyl)imidazo[1,2-a]pyrimidine is also used in organic synthesis as a versatile reactant. Its unique structure allows for a range of chemical reactions, facilitating the exploration of new synthetic pathways and the creation of complex organic molecules. This makes it an indispensable component in the development of new chemical entities with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1/C7H6ClN3/c8-4-6-5-11-3-1-2-9-7(11)10-6/h1-3,5H,4H2

Upstream product

• 109-12-6 2-aminopyrimidine 
• 53535-68-5 bromo-3-chloro-propanone 
• 534-07-6 1,3-Dichloroacetone 
• 504-29-0 2-aminopyridine 

Downstream Products

• 106012-56-0 3-formylimidazo<1,2-a>pyrimidine 
• 143982-40-5 2-formylimidazo<1,2-a>pyrimidine 

Relevant articles and documents

PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS

Described herein are compounds that activate pyruvate kinase R, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I): Formula (I) wherein R', R2, L', and L2 are as defined herein.

Imidazo[4,5-c]pyridine derivative and application thereof

The invention relates to a novel imidazo[4,5-c]pyridine derivative represented by a general formula I, and pharmaceutically acceptable salts, solvates or prodrugs of the novel imidazo[4,5-c]pyridine derivative, wherein the substituent R and R' are defined as in the specification. The invention also relates to an effect of the compound represented by the general formula I in inhibiting an NS5B RNA-dependent RNA polymerase (NS5B polymerase for short) which is necessary in a replication process of hepatitis c virus, also relates to an application of the compound, and pharmaceutically acceptable salts, hydrates or prodrugs of the compound in preparation of medicines for treating viral diseases, and especially relates to an application in preparation of medicines for treating and/or preventinghepatitis c.

Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B

The hepatitis C virus (HCV) NS5B polymerase is an attractive target for the development of novel and selective inhibitors of HCV replication. In this paper, the design, synthesis, and preliminary SAR studies of novel inhibitors of HCV NS5B polymerase based on the structure of tegobuvir have been described. The efforts to optimize the antiviral potency and reduce the treatment side effects with respect to genotype 1b resulted in the discovery of compound 3, which exhibited an EC50 of 1.163 nM and a CC50 >200 nM in a cell-based HCV replicon system assay. Additionally, testing for inhibition of the hERG channel showed a marked improvement over tegobuvir and the pharmacokinetic properties of compound 3 indicated that it was worthy of further investigation as a non-nucleoside inhibitor of HCV NS5B polymerase.

Synthesis and characterization of fused imidazole heterocyclic selenoesters and their application for chemical detoxification of HgCl2

A new series of selenoester derivatives of imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidine was synthesized under mild conditions using a simple methodology by the reaction of in situ generated sodium selenocarboxylates with 2-(chloromethyl)imidazo[1,2

TRIAZOLO- AND PYRAZOLOQUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITOR

The invention relates to compounds of the formula (I) and their use as pharmaceutical ingredients, in particular for the treatment of CNS related diseases.

Gonadotropin releasing hormone receptor antagonists

The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.

Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).

Reaction of 1,3-dibromo- and 1,3-dichloroacetone with 2-aminoazaheterocycles

The reactions of 1,3-dibromoacetone with 2-aminoazines and 2-aminoazoles has been carried out for the first time and the pure intermediate quaternary salts have been isolated. They undergo cyclization to the corresponding imidazoazines and imidazoazoles containing a bromomethyl group. Similar condensations were carried out with 1,3-dichloroacetone.

Synthese et Reactions SRN1 en Serie 3-Nitroimidazopyrimidine

A new heterocyclic reductive alkylating agent, 2-chloromethyl-3-nitroimidazopyrimidine, is synthesized for the first time and shown to react under phase-transfer catalysis conditions with 2-nitropropane anion to give good yield of the C-alkylated derivative.Elimination of nitrous acid allows to obtain a new class of imidazopyrimidine derivatives bearing a trisubstituted ethylenic bond in the 2 position.The SRN1 mechanism of C-alkylation is confirmed by classical inhibition experiments by dioxygen, p-dinitrobenzene or TEMPO.